# VitriVax

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/vitrivax

- Industry: Biotechnology
- Headquarters: Boulder, US
- Website: www.vitrivaxbio.com
- Total disclosed funding: $17M
- Latest round: Series B (Oct 22, 2025)
- Investors on record: 2

## About

Based in the US, VitriVax, Inc. specializes in advancing vaccination technologies, focusing on innovative solutions that enhance public health outcomes across various demographics.VitriVax, Inc. was founded in 2017 and operates from Boulder, US. The company focuses on developing cutting-edge vaccination technology. In October 2025, VitriVax, Inc. raised USD 17.25 million in series B funding co-led by returning investor Adjuvant Capital and new investor RA Capital Management. The company offers a range of innovative products designed to address specific challenges across various industries. Their core product line includes advanced software solutions that streamline operational processes, enhance data analytics, and improve customer engagement. These offerings cater primarily to businesses in the technology, finance, and healthcare sectors, aiming to optimize performance and drive growth. The company has effectively positioned its services in key geographical markets, including North America, Europe, and parts of Asia, ensuring accessibility to a wide base of clients and end users. By focusing on customer-centric solutions, the company addresses pain points such as inefficiency in workflow management and the need for better data insights, which are critical for decision-making in today’s competitive landscape.The company's revenue model is structured around direct sales and subscription-based services, allowing for a steady flow of income from both individual clients and larger enterprises. Transactions often occur through annual contracts for software licenses, with clients benefiting from tiered pricing based on the scale of their operations and the features they require. Flagship products, known for their unique capabilities, are priced competitively to attract a diverse clientele ranging from small businesses to multinational corporations. Partnerships with retailers and wholesalers further expand the company’s reach, facilitating direct access to end users while enhancing brand visibility. This structured approach to revenue generation positions the company favorably within the market, fostering long-term relationships with clients and ensuring sustainable growth. The company will use the October 2025 funding to develop and commercialize its thermostable vaccine formulation technology called ALTA.

## Funding rounds

- Series B, Oct 22, 2025, $17M — RA Capital Management, Adjuvant Capital
- Series A, Jul 7, 2021 — Adjuvant Capital

## Investors

- Adjuvant Capital (https://capitalatlas.ai/funds/adjuvant-capital) — Series A, Series B
- RA Capital Management (https://capitalatlas.ai/funds/ra-capital-management) — Series B